CROs & CDMOs
In this Issue:
From preclinical development to market approval, biopharma companies increasingly rely on outsourcing to biomanufacturing experts and contract research and contract packaging organisations: from hits to leads and proof-of-concept and from DoE, QbD over scaleable process development to customised and even continuous USP, DSP, polishing, sterile filling including serialisation. However, as novel formats for biologics and biosimilars emerge, diversification through special knowhow is key to market success. New formulations, delivery forms, trial formats and patient enrolment strategies also challenge the growing industry.
You want to be part of the next issue of European Biotechnology?